Skip to main content
Search

University Health Network

3 related articles

Subscribe to updates
  1. A 45-member modified Delphi consensus: screen for eating disorders before GLP-1 receptor agonist prescribing, and generally avoid these agents in active anorexia and bulimia nervosa

    Using a three-round modified Delphi method, a 45-member panel of clinicians and researchers in diabetes, obesity and/or eating disorders plus people with lived experience reached an average 91.7% consensus on recommendations for GLP-1 receptor agonist use in eating disorder contexts, covering pre-treatment screening, risk-stratified monitoring, standardized educational materials and concurrent evidence-based psychotherapy, stating that these agents should generally be avoided in active eating disorders, particularly anorexia nervosa, atypical anorexia nervosa and bulimia nervosa with marked dietary restraint and/or significant weight suppression, and setting out research priorities in epidemiology, regulation and binge eating disorder trials.

  2. bioRxiv

    A single intra-articular injection of TGFB1-engineered iMSCs lowered synovial macrophage numbers and the MHCII/CD206 ratio in a mouse osteoarthritis model but did not reduce cartilage degeneration

    The study benchmarked a doxycycline-inducible, hTERT-immortalized iPSC-derived mesenchymal stromal cell line engineered to overexpress TGFB1 (TGFB1-iMSCs) against multiple adipose tissue-derived MSC (MSC(AT)) donors across predefined immunomodulatory and angiogenic potency attributes, finding that TGFB1-iMSCs were smaller and more circular with comparable or higher proliferative rates, had a distinct angiogenic signature (EDIL3, EDN1, PDGFA) and nine differentially expressed microRNAs, secreted less VEGF with intermediate HUVEC tube formation, yet matched or exceeded all MSC(AT) donors in a monocyte-macrophage transwell immunomodulatory assay; in a murine DMM post-traumatic osteoarthritis model, a single intra-articular injection of TGFB1-iMSCs, but not MSC(AT), reduced total synovial macr

  3. Cancer

    The Evolving Role of Immunotherapy in Ovarian Cancer: From Empirical Use Toward Biology-Driven Combination and Precision Strategies

    This review synthesizes the clinical evidence and resistance mechanisms for immunotherapy in ovarian cancer, noting that single-agent immune checkpoint inhibitors achieve objective response rates generally below 15% in recurrent disease, that the clearest added benefit appears in chemotherapy-based combinations for PD-L1-positive platinum-resistant disease (e.g., in ENGOT-ov65/KEYNOTE-B96, median overall survival 18.2 vs 14.0 months in the CPS >=1 population, HR 0.

You’re all caught up